ArticleCell reports. Medicine2026

Phase 1 study of intracranial T cell therapy with pemetrexed for refractory brain metastases and glioblastomas.

Congcong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.